

Safety and Efficacy Results from the REVEAL Part A Phase 1/2 Trial of TSHA-102 in Pediatric and Adolescent/Adult Cohorts

Elizabeth Berry-Kravis¹, Robert Haas², Robin Ryther³, Tim Feyma⁴, Inge Meijer⁵, Colleen Buhrfiend¹, Tessa Clarkson⁶, Rumana Haque-Ahmed⁷, Laura Pisani⁷, Jason Cataldo⁷, Minna Montgomery⁷, Suku Nagendran⁷ and Elsa Rossignol⁵

¹Departments of Pediatrics, Neurological Sciences, Anatomy and Cell Biology, Rush University Medical Center, Chicago, IL, USA; ²University of California San Diego, San Diego, CA, USA; ³Washington University School of Medicine, St. Louis, MO, USA; ⁴Gillette Children's Specialty Healthcare, St. Paul, MN, USA; ⁵Departments de Neurosciences and Pediatric, Université de Montréal and Centre Universitaire Hospitalier Sainte-Justine, Montreal, Quebec, Canada; ⁶Psychomere, Littleton, CO, USA; ⁷Taysha Gene Therapies, Dallas, TX, USA

Poster 264


Aims

To investigate the safety and preliminary efficacy of low- and high-dose TSHA-102 in adolescent/adult and pediatric females with Rett syndrome (RTT)

Background


- RTT disease presentation and progression is highly heterogeneous, with inter-individual variability in the timing and pattern of lost or missed developmental milestones (DM), impacting activities of daily living¹⁻⁴
- A recent analysis of Natural History Study (NHS) data demonstrated that patients reach a developmental plateau at ≥6 years of age⁴, with a <6.7% likelihood of gaining new or regaining lost developmental milestones among a defined list of 28 (Figure 1)⁵

Figure 1: Rigorous analysis of the Rett Natural History Study demonstrated likelihood of gaining/regaining any of the 28 defined DMs is predictable in patients ≥6 years of age



- Gaining or regaining a DM would not be expected from individuals in the developmental plateau population
- While current care aims to manage symptoms, there are no approved disease-modifying strategies that address the genetic root cause of RTT (loss of function mutation in the methyl-CpG-binding protein 2 [MECP2] gene)⁶
- TSHA-102 is a one-time gene therapy for RTT, designed to enable optimal and controlled transgene expression of MECP2 across the CNS following intrathecal administration (Figure 2)^{7,8}
- The REVEAL pivotal trial is investigating TSHA-102 for adolescent/adult (NCT05606614) and pediatric (NCT06152237) individuals with RTT^{9,10}
- Here, we present longer-term safety and efficacy data from REVEAL Part A, including all 12 patients with ≥12 months of follow-up, with data extending up to 30 months for the earliest treated patient

Figure 2: TSHA-102 construct: An investigational one-time gene therapy designed to regulate MECP2



Methods

- REVEAL is an ongoing Phase 1/2, open-label, dose-escalation (Part A) and dose-expansion (Part B), registrational, multi-center trial, using each patient as their own control; ≥12-month Part A data is reported here (Figure 3)^{9,10}
- Safety monitoring included clinical/laboratory evaluations

Figure 3: REVEAL Part A study overview^{9,10}

Objectives

- TSHA-102 safety and preliminary efficacy
- Evaluate two dose levels to, if possible, establish maximum administered dose (MAD) or maximum tolerated dose (MTD)

Low Dose:
5.7x10¹⁴ total vg N=4

High Dose:
1.0x10¹⁵ total vg N=8

Key Inclusion Criteria

- Females with pathogenic confirmation of MECP2 mutation
- Clinical Global Impression Scale-Severity (CGI-S) score ≥4 at screening

Key Assessments

- Developmental Milestones Gain/regain
 - ORCA
 - MSEL-A
- R-MBA
 - CGI-S
 - CGI-I

- Primary evidence of efficacy (DM gain or regain): Applied rigorous evaluation criteria to available video-evidenced DM data that enabled a reliable, objective assessment of TSHA-102 efficacy (Figure 4)
- Supportive evidence of functional gain: Supplemental analysis of skills and improvements derived from structured assessments (MSEL-A, R-MBA, and ORCA) demonstrated additional functional skill gains and improvements across core disease characteristics outside of the natural history defined DMs, which further highlight the broad therapeutic impact of TSHA-102 on activities of daily living (Figure 4)

Figure 4: Rigorous evaluation criteria applied to Part A data enabled reliable, objective assessment of TSHA-102 efficacy

Primary Evidence of Efficacy

Developmental Milestones (DM)

The functional gain of zone of the 28 DMs defined in the natural history study assessed via rigorous video-evidenced evaluation

Evaluation Criteria:

- Baseline:** Video data/medical history confirming milestone was either never gained or lost sufficiently long ago, such that the likelihood of spontaneous gain/regain is <6.7%
- Post-treatment:** Video-documentation of milestone demonstration
- Evaluation method:** Determined by multiple independent central raters based on prespecified definitions of achievement for each milestone

Additional evidence of functional gain

Functional gain or improvement in a core disease characteristic beyond the 28 natural history defined DMs assessed via rigorous video-evidenced evaluation and validated scales

Evaluation Criteria:

- Adapted Mullen Scales of Early Learning (MSEL-A):** Centrally rated video-recorded evaluation assessing expressive / receptive language skills
- Observer-Reported Communication Ability (ORCA):** Caregiver-reported structured evaluation assessing communication skills
- Revised Motor Behavior Assessment (R-MBA):** Clinician-reported video evaluation assessing frequency, severity or independence of Rett syndrome characteristics

n=8 patients with ORCA data, n=7 with MSEL-A data, and n=12 with R-MBA data.

Results

Baseline characteristics

- As of May 2026 data cut, 12 patients (low dose, N=4; high dose, N=8) had received TSHA-102. Patients were 6–21 YOA, with diverse clinical histories, broad disease severity (CGI-S 4 to 6), and varied MECP2 mutations to reflect a real-world population

Safety

- TSHA-102 was generally well tolerated at the low and high dose, with no treatment-related serious adverse events (SAEs) or dose-limiting toxicities (DLT) (Table 1)
- All TEAEs considered related to TSHA-102 were mild-moderate in severity, with the most common being elevated liver enzymes* (n=4, 33%), CSF protein increased (n=3, 25%) (clinically insignificant), pyrexia (n=3, 25%)
- Seizures have generally been well controlled following TSHA-102

*Includes preferred terms: Gamma-glutamyltransferase increased, Hypermtransaminasaemia, Liver function test increased, Transaminases increased.

Table 1: Events across the 12 pediatric, adolescent, and adult patients dosed in Part A of REVEAL Phase 1/2 trials

	Low Dose 5.7x10 ¹⁴ vg (N=4)		High Dose 1x10 ¹⁵ vg (N=8)		Total (N=12)	
	N	E	N	E	N	E
TEAE Related to TSHA-102	4	17	5	20	9	37
Serious TEAE Unrelated to TSHA-102	3	9	4	8	7	17
Serious TEAE Related to TSHA-102	0	0	0	0	0	0

Efficacy

Table 2: All 12 pediatric, adolescent, and adult patients across a broad range of disease severity gained/regained zone developmental milestone post-TSHA-102*

	Age at dosing (years)	Baseline CGI-S Score		Post-treatment follow-up (months)	DM gain post-TSHA-102
		N	E		
Low Dose 5.7x10 ¹⁴ vg	20	6		30	✓
	21	4		30	✓
	6	5		24	✓
	7	4		24	✓
	15	5		18	✓
High Dose 1x10 ¹⁵ vg	21	5		18	✓
	8	5		18	✓
	15	5		12	✓
	16	5		12	✓
	6	4		12	✓
	7	6		12	✓
	6	5		12	✓

- TSHA-102 delivered consistent and clinically meaningful treatment benefit across pediatric and adolescent/adult patients with RTT
- 16 DMs in pediatric (n=6) and 15 DMs in adolescent/adult (n=6) patients support the broad treatment potential of TSHA-102

Figure 5: Rapid and robust response rate in REVEAL Part A supports the pivotal trial is well-powered to establish efficacy




Figure 6: 31 total developmental milestones achieved across core disease domains post-TSHA-102 reflect meaningful improvements in daily living

Communication

- Spoke in phrases with meaning
- Used word(s) with meaning
- Followed a command without a gesture
- Followed a command with a gesture
- Pointed for something they wanted
- Identified body parts

Enable expression of needs, preferences, emotions, and foster social connections

Fine Motor

- Used utensils to eat without assistance
- Used utensils to eat with assistance
- Finger fed
- Transferred an object from one hand to another
- Used a pincer grasp
- Reached for a toy
- Holds bottle unproppped

Reflect self-care skills and purposeful hand use that enable independence

Gross Motor


- Walked with support
- Climbed down stairs with support
- Stood while holding on
- Pulled to standing
- Sat without support

Enhance mobility and independence, and reduce the physical burden of caregiving

Conclusions

- No treatment-related SAEs or DLTs observed in any patients, with all patients having ≥12 months of follow-up
- 100% of patients (N=12, 6–21 years) in developmental plateau population of gained/regained zone DM
- Longer follow-up demonstrates a durable and deepening treatment effect across all patients, with additional functional gains continuing to accumulate over time ≥12 months
 - DM gains increased by 69% from 6 to 12 months and by 94% from 6 to ≥12 months post TSHA-102
 - Patients with longest follow-up at 30 months continue to demonstrate functional gains/improvements
- Broad functional impact consistently demonstrated across core disease domains post-TSHA-102 regardless of age, disease severity or genotype
 - At ≥12 months post-TSHA-102, a total of 310 functional gains and improvements were observed (~26 per patient), comprising 31 DMs and 279 additional skill gains/improvements
 - Durable, multi-domain gains enable independent engagement in daily activities, reduce caregiver burden and enhance social engagement
- Robust, clinically meaningful responses at 6 and ≥12 months exceed FDA-aligned minimum threshold for efficacy and support potential for BLA submission based on REVEAL pivotal trial 6-month interim analysis

Figure 7: Patients achieved durable, clinically meaningful skill gains and improvements that accumulated over time in addition to developmental milestones



*Gain/regain of zone of the 28 natural history-defined developmental milestones from the REVEAL pivotal trial primary endpoint. *Skill gains/improvements derived from MSEL-A, R-MBA and ORCA: N=8 patients with ORCA data, N=7 with MSEL-A data, and N=12 with R-MBA data. *N=7 patients with data >12 months post-TSHA-102, N=5 patients with 12-month data.

- ~26 functional gains per patient across core disease domains reflect the broad functional impact demonstrated post-TSHA-102

Figure 8: TSHA-102 delivers durable, multi-domain functional gains that enable activities of daily living

Communication improvements

Pre-TSHA-102	Post-TSHA-102
Non-verbal	Speaks in phrases/sentences with meaning
Understood simple words	Engages in conversations and play/activity with others
Made choices <10% of time using eye gaze	Makes choices 100% of time by pointing
Rarely responds to spoken words	Follows directions and responds to questions

Fine motor improvements

Pre-TSHA-102	Post-TSHA-102
Required caregiver-assisted feeding	Finger feeds and uses utensils to eat independently
No purposeful hand use	Plays with toys and self-feeds
Stereotypies 76-100% of time	Stereotypies 1-25% of time
Limited hand function	Holds a bottle unproppped


Gross motor improvements

Pre-TSHA-102	Post-TSHA-102
Non-ambulatory	Walks with support
Unable to use stairs	Climbs down stairs with support
Needed caregiver assistance	Pulls self to standing position and stands while holding on
Most severe dystonia (fixed positional deformity)	No dystonia

Autonomic/Other improvements

Pre-TSHA-102	Post-TSHA-102
Unable to eat by mouth and required a g-tube	Eats/drinks by mouth
Weekly to monthly seizure episodes	Seizure-free ≥6 months
Hyperventilating/ breath holding 26-50% of time	Absent or reduced hyperventilating/ breath holding
Feeding took >30 minutes	No feeding difficulties

Figure 9: R-MBA score mean change from baseline in patients ≥6 years: REVEAL low and high-dose patients vs natural history*, indicating a reversal in the disease trajectory



N=12 at 6 and 12 months, N=7 at ≥18 months post-TSHA-102. Statistical analyses are based on May 2026 data cutoff (N=12). *R-MBA assessed in Rett syndrome NHS at ~6 and ~12 months; MBA natural history data converted to R-MBA, mean scores reported were calculated from baseline to 6 and 12 months; Accessed from International Rett Syndrome Foundation (IRSF). ClinicalTrials.gov: NCT02738281: a prospective cohort of individuals with a pathologic mutation in the MECP2 gene, commonly associated with RTT.

Table 3: Robust and clinically meaningful responses at 6 and ≥12 months support potential for BLA submission based on the 6-month interim analysis from REVEAL pivotal trial

Endpoint		6 months N=12	12 months N=12	≥18 months N=7
Functional Gains	% of Patients Gained/Regained ≥One Developmental Milestone	83%	100%	100%
	Average Functional Gains Per Patient	22 gains per patient	23 gains per patient	26 gains per patient
R-MBA*	Statistically Significant Mean Score Improvement vs Natural History	-11.0 P = 0.0011	-10.3 P = 0.0002	-11.0 P = 0.0046
CGI-I	% of Patients with CGI-I Score ≤3 at Multiple Post-treatment Assessments	100%	100%	100%
CGI-S**	% of Patients with CGI-S Total Score Improvement	25%	25%	57%

*R-MBA mean score change post-TSHA-102 is relative to baseline; lower score=improvement from baseline. **CGI-S: a clinician-assessed scale ranging from 1 to 7, assessing severity of illness.

Key takeaways

- TSHA-102 continues to be generally well-tolerated in pediatric, adolescent, and adult patients with RTT
- Longer-term follow-up showed a durable and deepening treatment effect ≥12 months post-TSHA-102, with functional gains accumulating over time across core disease domains
- 310 total functional gains demonstrated ≥12 months post-TSHA-102 (~26 per patient), comprising 31 developmental milestones and 279 additional skill gains/improvements
- Robust and clinically meaningful responses at both 6 and ≥12 months in REVEAL Part A further support potential for BLA submission based on REVEAL pivotal trial 6-month interim analysis

Presenting author: Dr. Elsa Rossignol (elsa.rossignol@umontreal.ca)
Acknowledgments: Studies funded by Taysha Gene Therapies. Medical writing support for this poster was provided by Leigh O'Connor-Jones, PhD and Lauren Batt, PhD, of Avalere Health US Inc., funded by Taysha Gene Therapies.
Disclosures: ER: Consultancy with Acadia Pharmaceuticals, CACNA1A Foundation, Canadian Pediatric Epilepsy Network, Canadian Association for Neurosciences, and Taysha Gene Therapies; Clinical Trials with Ionis Pharmaceuticals and Taysha Gene Therapies; Grants from CACNA1A Foundation; Canada Foundation for Innovation; Canadian Institutes of Health Research, Canada Research Chairs; CHU Saint-Justine, Ontario Rett Syndrome Association; CHUSJ-SickKids Precision in Child Health Partnership (PCHP); Université de Montréal.

The authors wish to thank all patients and caregivers, as well as the study staff who make this research possible

Abbreviations: AAV9, adeno-associated virus serotype 9; BLA, biologics license application; CGI-I, Clinical Global Impression Scale-Improvement; CGI-S, Clinical Global Impression Scale-Severity; CNS, central nervous system; CSF, cerebrospinal fluid; DLT, dose-limiting toxicity; DM, developmental milestone; E, number of events; MECP2, methyl-CpG-binding protein 2; miRARE, microRNA autoregulatory element; MSEL-A, Adapted Mullen Scales of Early Learning; N, number of patients; NHS, Natural History Study; ORCA, Observer-Reported Communication Ability; R-MBA, Revised Motor Behavior Assessment; RTT, Rett syndrome; SAE, serious adverse event; sc, self-complementary; SD, standard deviation; TEAE, treatment-emergent adverse event; vg, vector genome; YOA, years of age.
References: 1. Neul JL, et al. *J Neurodev Disord.* 2016;4(1):20. 2. May D, et al. *J Neurodev Disord.* 2024;16(1):42. 3. Einspieler C, Marschik PB. *Neurosci Biobehav Rev.* 2019;98:320–32. 4. Neul JL, et al. *J Neurodev Disord.* 2026;18(1):20. 5. Montgomery M, et al. Presented at 2026 IRSF Rett Syndrome Scientific Meeting; June 29–July 1, Prior Lake, MN, USA (poster 39). 6. Samanta D. *Front Neurol.* 2026;17:1766679. 7. Sinnott SE, et al. *Brain.* 2021;144(10):3005–19. 8. Sadhu C, et al. *Genes.* 2024;15(1):31. 9. ClinicalTrials.gov: NCT05606614. Accessed May 2026; 10. ClinicalTrials.gov: NCT06152237. Accessed May 2026; 11. Li X, et al. *Int J Mol Sci.* 2023;24(9):7736. 12. McCarty DM. *Mol Ther.* 2008;16(10):1648–1656. 13. Tillotson R, et al. *Nature.* 2017;550(7676):398–401. 14. Haque E, et al. *Front Med.* 2026;13:1819594. 15. Haque E, et al. Presented at 2025 IRSF Rett Syndrome Scientific Meeting; June 9–11, 2025.

Previously presented at IRSF Rett Syndrome Scientific Meeting 2026 | June 29–July 1 | Prior Lake, MN, USA
55th CNS Annual Meeting | October 14–17, 2026 | Montréal, Québec, Canada



Taysha
GENE THERAPIES